Etomidate ameliorated advanced glycation end-products (AGEs)-induced reduction of extracellular matrix genes expression in chondrocytes
Authors:
Open Access
- 1 January 2021
- journal article
- research article
- Published by Taylor & Francis in Bioengineered
- Vol. 12 (1) , 4191-4200
Abstract
Osteoarthritis (OA) is a rheumatic disease common in the elderly. AGEs are the end products of glycation reactions and play an important role in the development of OA. Etomidate is a general anesthesia-inducing agent recently reported to exert significant anti-inflammatory effects. The present study aims to explore the protective effect of Etomidate against advanced glycation end-products (AGEs)-induced reduction of extracellular matrix gene expression in chondrocytes. In the present study, we found that AGEs significantly reduced the expression of Collagen II (COL2A1) and Aggrecan (ACAN) at the gene level. Furthermore, AGEs inhibited the expression of SRY-related high mobility group-box gene 9 (SOX-9), promoting the expression of COL2A1 and ACAN. COL2A1, ACAN, and SOX-9 in chondrocytes were significantly elevated by treatment with Etomidate alone. Consistently, Etomidate ameliorated AGEs-induced downregulation of COL2A1, ACAN, and SOX-9 in a dose-dependent manner. Importantly, we found that knockdown of SOX-9 eliminated the beneficial effects of Etomidate against AGEs-induced decrease in COL2A1 and ACAN genes. Based on these findings, we demonstrated that Etomidate could ameliorate AGEs-induced reduction of extracellular matrix gene expression in chondrocytes by upregulating SOX-9. Graphical abstractKeywords
This publication has 43 references indexed in Scilit:
- Knee replacementThe Lancet, 2012
- Distal Interleukin-1β (IL-1β) Response Element of Human Matrix Metalloproteinase-13 (MMP-13) Binds Activator Protein 1 (AP-1) Transcription Factors and Regulates Gene ExpressionJournal of Biological Chemistry, 2012
- Recent progress in understanding molecular mechanisms of cartilage degeneration during osteoarthritisAnnals of the New York Academy of Sciences, 2011
- Aging and osteoarthritis: the role of chondrocyte senescence and aging changes in the cartilage matrixOsteoarthritis and Cartilage, 2009
- Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part IIArthritis & Rheumatism, 2007
- Energy metabolism, altered proteins, sirtuins and ageing: converging mechanisms?Biogerontology, 2007
- Advanced glycation end products increases matrix metalloproteinase‐1, ‐3, and ‐13, and TNF‐α in human osteoarthritic chondrocytesFEBS Letters, 2007
- Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-jun N-terminal kinase, and nuclear factor κB: Differential regulation of collagenase 1 and collagenase 3Arthritis & Rheumatism, 2000
- SOX9 directly regulates the type-ll collagen geneNature Genetics, 1997
- ETOMIDATE, A NEW WATER-SOLUBLE NON-BARBITURATE INTRAVENOUS INDUCTION AGENTThe Lancet, 1975